Noninferiority of a Shorter 6-Month Multidrug Regimen for Rifampicin-Resistant Pulmonary Tuberculosis

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  New England Journal of Medicine https://doi.org/10.1056/NEJMoa2503687
Dr. Francesca Conradie  et al.

Points

A landmark clinical trial conducted across South Africa successfully established that a shortened six-month oral regimen is noninferior to the traditional nine-month standard of care for drug-resistant tuberculosis.
Investigating a streamlined four-to-five drug protocol featuring bedaquiline and delamanid, researchers effectively reduced treatment duration while maintaining a therapeutic efficacy and safety profile comparable to longer therapies.
Demonstrating exceptional methodological inclusivity, the study safely evaluated the shortened regimen within historically neglected patient populations including young pediatric cohorts, breastfeeding mothers, and ten pregnant individuals.
Global therapeutic guidelines from the World Health Organization have been directly transformed by these findings, which promote simplified family-wide adherence strategies to drastically lower worldwide disease mortality.
Active tuberculosis continues to present a major public health crisis in South Africa, where tens of thousands of individuals succumb to the highly infectious pulmonary disease annually.

Summary

This phase 3, open-label, pragmatic, randomized noninferiority trial evaluated a shortened, oral treatment strategy for pulmonary rifampicin-resistant tuberculosis in South Africa. Of 432 individuals screened during the COVID-19 pandemic, 403 underwent randomization, allocating 203 participants to the novel 6-month trial strategy and 200 to the 9-month standard-of-care control group. Crucially, the trial employed an inclusive methodology by enrolling pediatric patients, breastfeeding mothers, and 10 pregnant women, cohorts historically excluded from drug-resistant tuberculosis research.

The investigative regimen streamlined therapy from a seven-drug protocol down to four or five oral medications administered over 6 months, incorporating bedaquiline, delamanid, linezolid, and levofloxacin or clofazimine, or both. The standard-of-care control group received a minimum 9-month regimen. The primary efficacy endpoint was a successful outcome, defined as clinical, radiologic, or bacteriologic cure or treatment completion evaluated at 76 weeks post-randomization, utilizing a 10-percentage-point noninferiority margin.

Efficacy outcomes demonstrated a successful treatment resolution in 174 of 202 participants (86.1%) in the trial-strategy group compared to 172 of 200 participants (86.0%) in the control cohort. The adjusted risk difference was -0.2 percentage points (95% CI, -6.9 to 6.5; P = 0.001 for noninferiority), establishing the noninferiority of the shorter protocol. Safety profiles were highly comparable; grade 3 or higher adverse events occurred in 31.2% (63/202) of the experimental arm versus 37.0% (74/200) of the control group, with exactly 10 deaths reported in each cohort. Among the 10 pregnant women, 9 achieved successful cure, and all delivered healthy live births. These findings confirm that a simplified, family-wide treatment strategy matches standard-of-care efficacy while optimization simplifies real-world clinical compliance.

Link to the article: https://www.nejm.org/doi/10.1056/NEJMoa2503687

References

Conradie, F., Badat, T., Poswa, A., Rajaram, S., Kooverjee, S., Maartens, G., Meintjes, G., Hughes, J., Schaaf, H. S., Howell, P., Ndjeka, N., & Phillips, P. P. J. (2026). A pragmatic trial of a 6-month strategy for rifampicin-resistant tuberculosis. New England Journal of Medicine, 394(24), 2429–2439. https://doi.org/10.1056/NEJMoa2503687